Aubagio(R) significantly reduced risk of relapse & lesions

[MSUK]

Aubagio(R) significantly reduced risk of new clinical relapse or MRI lesion in MS study

Genzyme, a Sanofi company , announced positive new data from the TOPIC study of its once-daily, oral Aubagio(R) (teriflunomide). These new data, presented today at the 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS), include the following:

-- Aubagio 14 mg significantly reduced the risk of a new clinical relapse or MRI lesion over the two-year study period. There was a 35 percent reduction among patients who received Aubagio 14 mg compared to placebo (p=0.0003).

-- As measured by MRI over the two-year study period, there was a 5 percent increase in total lesion volume among patients treated with Aubagio 14 mg compared to a 28 percent increase among patients treated with placebo (p=0.0374). In addition, there was a 59 percent reduction in gadolinium-enhancing T1 lesions among patients treated with Aubagio 14 mg compared to placebo (p=0.0008).... Read More - http://www.ms-uk.org/aubagio